Full Year Guidance
Organon does not provide GAAP financial measures on a forward-looking basis because the company cannot predict with reasonable certainty and without unreasonable effort, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts, and acquisition-related expenses. These items are uncertain, depend on various factors, and could be material to Organon's results computed in accordance with GAAP.
Full year 2024 actual results and 2025 financial guidance are presented below on a non-GAAP basis, except revenue.
| Full Year 2024 Actuals | Full Year 2025 Guidance | |
| Revenue | $6.403B | $6.125B-$6.325B |
| FX translation headwind | ~$80M | ~$200M |
| Adjusted gross margin | 61.6% | 60.0%-61.0% |
| SG&A | $1.57B/25% | Mid-20% range |
| R&D | $440M/6.9% | Upper single-digit |
| IPR&D* | $81M | - |
| Adjusted EBITDA margin (Non-GAAP) | 30.6% | 31.0%-32.0% |
| Interest | $520M | ~$510M |
| Depreciation | $126M | ~$135M |
| Effective non-GAAP tax rate | 18.8% | 22.5%-24.5% |
| Fully diluted weighted average shares outstanding | 259M | ~263M |
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。